Updated National Study of Functional Graft Renal Cell Carcinomas: Are They a Different Entity?
Journal
Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
20
08
2022
revised:
24
09
2022
accepted:
26
09
2022
pubmed:
16
10
2022
medline:
11
1
2023
entrez:
15
10
2022
Statut:
ppublish
Résumé
To analyze de novo graft carcinoma characteristics from our updated national multicentric retrospective cohort. Thirty-two transplant centers have retrospectively completed the database. This database concerns all kidney graft tumors including urothelial, and others type but excludes renal lymphomas over 31 years. One hundred and fifty twokidney graft carcinomas were diagnosed in functional grafts. Among them 130 tumors were Renal Cell Carcinomas. The calculated incidence was 0.18%. Median age of the allograft at diagnosis was 45.4 years old. The median time between transplantation and diagnosis was 147.1 months. 60 tumors were papillary carcinomas and 64 were clear cell carcinomas. Median tumor size was 25 mm. 18, 64, 21 and 1 tumors were respectively Fuhrman grade 1, 2, 3 and 4. Nephron sparing surgery (NSS) was performed on 68 (52.3%) recipients. Ablative therapy was performed in 23 cases (17.7%). Specific survival rate was 96.8%. This study confirmed that renal graft carcinomas are a different entity: with a younger age of diagnosis; a lower stage at diagnosis; a higher incidence of papillary subtypes.
Identifiants
pubmed: 36243142
pii: S0090-4295(22)00829-9
doi: 10.1016/j.urology.2022.09.020
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
152-157Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.